Borja Ibáñez

Borja Ibáñez

doctor Spain

Borja Ibáñez is the scientific director of the National Center for Cardiovascular Research (CNIC) and an interventional cardiologist at the Hospital Fundación Jiménez Díaz. He is recognized for his work in cardiovascular research and healthcare.

Born on Jan 01, 1973 (52 years old)

Global Media Ratings
Dominance
0.01%
Persistence
0 wks
Reach
184,349
Power
9,313$
Sentiment
8.76
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
United States 1 9.00 0.04% +0% 331,002,651 126,192 $21,000,000 8,006$
Dominican Republic 1 8.00 0.08% +0% 10,847,910 9,025 $89,000 74$
Spain 1 8.00 0.07% +0% 46,754,778 35,049 $1,400,000 1,049$
Romania 1 7.00 0.07% +0% 19,237,691 14,083 $250,000 183$
Totals 4 407,843,030 184,349 $22,739,000 9,312$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Romania Romania: Borja Ibáñez is the scientific director at the National Center for Cardiovascular Research in Madrid and co-author of the study discussing the ineffectiveness of beta-blockers. 7

Adevărul: Un medicament comun pentru inimă, luat de milioane de oameni, ar putea crește riscul de deces

Dominican Republic Dominican Republic: Borja Ibáñez is the principal investigator of the REBOOT trial and a cardiologist at the Hospital Universitario Fundación Jiménez Díaz. 8

Listín Diario – oldest Dominican newspaper, est. 1889: Estudio revela que tras un infarto mujeres tienen peor pronóstico cuando usan betabloqueantes

Spain Spain: Borja Ibáñez is a cardiologist leading a study that reveals beta-blockers are ineffective for most patients post-heart attack. 8

El País: Betabloqueantes: Más de un millón de personas en España toman cada día un tratamiento contra el infarto que no sirve para nada | Ciencia

United States United States: Borja Ibáñez is the lead study author and scientific director for Madrid’s National Center for Cardiovascular Investigation. 9

CNN: Some women have higher risk of death on common heart attack medication, study finds